AstraZeneca breast cancer pill fails pivotal first-line trial

AstraZeneca's breast cancer pill failed a pivotal trial as first-line therapy in advanced tumors, a setback for the drug's expansion. The failure raises uncertainty about the drug's regulatory and commercial prospects. This continues a pattern of recent trial setbacks for AstraZeneca in oncology.